PF-08046052

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NamePF-08046052
Drug Alias NameLAVA-1223SGN-EGFRd2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Epidermal growth factor receptor erbB1 +[4] 
TargetsEpidermal growth factor receptor erbB1T cell receptor delta variable 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVu University Medical CenterLava Therapeutics NVSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesLava Therapeutics NV
Inactive CompaniesSeagen Inc
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 

Other Information

ATC CodeN/A
Related LinksN/A